Wafaa El-Sadr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8969632/publications.pdf

Version: 2024-02-01

156 papers 8,561 citations

39 h-index 48315 88 g-index

164 all docs

 $\begin{array}{c} 164 \\ \\ \text{docs citations} \end{array}$

164 times ranked 9435 citing authors

#	Article	IF	CITATIONS
1	Association of sociodemographic factors with needle sharing and number of sex partners among people who inject drugs in Egypt. Global Public Health, 2022, 17, 1689-1698.	2.0	5
2	Effects of the Coronavirus Disease 2019 Pandemic on Human Immunodeficiency Virus Services: Findings from 11 Sub-Saharan African Countries. Clinical Infectious Diseases, 2022, 75, e1046-e1053.	5.8	17
3	"What will we do if we get infected?― An interview-based study of the COVID-19 pandemic and its effects on the health and safety of sex workers in the United States. SSM Qualitative Research in Health, 2022, 2, 100027.	1.5	7
4	Effect of COVID-19 Pandemic on Older New York City Residents Living at Home. Journal of Community Health, 2022, 47, 361-370.	3.8	3
5	Assessing the Information-Motivation-Behavioral Skills Model to Predict Pre-exposure Prophylaxis Adherence Among Black Men Who have Sex with Men and Transgender Women in a Community Setting in New York City. AIDS and Behavior, 2022, 26, 2494-2502.	2.7	8
6	Is Omicron Showing Us the Path Ahead?. American Journal of Public Health, 2022, , e1-e2.	2.7	2
7	Public Health Implications of Adapting HIV Pre-exposure Prophylaxis Programs for Virtual Service Delivery in the Context of the COVID-19 Pandemic: Systematic Review. JMIR Public Health and Surveillance, 2022, 8, e37479.	2.6	13
8	Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain. Scientific Reports, 2022, 12, .	3.3	9
9	Contact Tracing: Barriers and Facilitators. American Journal of Public Health, 2022, 112, 1025-1033.	2.7	15
10	COVID-19 Vaccine Uptake and Factors Associated With Being Unvaccinated Among Lesbian, Gay, Bisexual, Transgender, Queer, and Other Sexual Identities (LGBTQ+) New Yorkers. Open Forum Infectious Diseases, 2022, 9, .	0.9	9
11	The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D Study. Journal of Infectious Diseases, 2021, 223, 632-637.	4.0	6
12	Examining stigma, social support, and gender differences in unsuppressed HIV viral load among participants in HPTN 065. Journal of Behavioral Medicine, 2021, 44, 159-171.	2.1	8
13	Life in the Balance: Young Female Sex Workers in Kenya Weigh the Risks of COVID-19 and HIV. AIDS and Behavior, 2021, 25, 1323-1330.	2.7	20
14	Costâ€effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States. Journal of the International AIDS Society, 2021, 24, e25690.	3.0	5
15	COVID-19 testing, case, and death rates and spatial socio-demographics in New York City: An ecological analysis as of June 2020. Health and Place, 2021, 68, 102539.	3.3	40
16	Improving child tuberculosis contact identification and screening in Lesotho: Results from a mixed-methods cluster-randomized implementation science study. PLoS ONE, 2021, 16, e0248516.	2.5	7
17	Bringing HIV services to key populations and their communities in Tanzania: from pilot to scale. Journal of the International AIDS Society, 2021, 24, e25718.	3.0	5
18	Ending AIDS as a public health threat by 2030: Time to reset targets for 2025. PLoS Medicine, 2021, 18, e1003649.	8.4	23

#	Article	IF	CITATIONS
19	Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. Annals of Internal Medicine, 2021, 174, 768-776.	3.9	14
20	Beyond the Magic Bullet: What Will It Take to End the AIDS Epidemic?. American Journal of Public Health, 2021, 111, 1234-1236.	2.7	3
21	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. Nature Communications, 2021, 12, 4450.	12.8	67
22	The Looming Threat: Cancer in Sub-Saharan Africa. Oncologist, 2021, 26, e2099-e2101.	3.7	3
23	Integrating HIV services and other health services: AÂsystematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003836.	8.4	38
24	How can progress towards Ending the HIV Epidemic in the United States be monitored?. Clinical Infectious Diseases, 2021, , .	5.8	4
25	HIV incidence, viremia, and the national response in Eswatini: Two sequential population-based surveys. PLoS ONE, 2021, 16, e0260892.	2.5	9
26	What one pandemic can teach us in facing another. Aids, 2020, 34, 1757-1759.	2.2	9
27	Covid-19, Ebola, and HIV â€" Leveraging Lessons to Maximize Impact. New England Journal of Medicine, 2020, 383, e106.	27.0	17
28	Changes in D-dimer after initiation of antiretroviral therapy in adults living with HIV in Kenya. BMC Infectious Diseases, 2020, 20, 508.	2.9	6
29	Challenges and Opportunities in China's Health Aid to Africa: Findings from Qualitative Interviews in Tanzania and Malawi. Globalization and Health, 2020, 16, 71.	4.9	10
30	Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 33, 1-10.	1.2	4
31	Provider attitudes about childhood tuberculosis prevention in Lesotho: a qualitative study. BMC Health Services Research, 2020, 20, 461.	2.2	10
32	Africa in the Path of Covid-19. New England Journal of Medicine, 2020, 383, e11.	27.0	182
33	Expansion and scale-up of HIV care and treatment services in four countries over ten years. PLoS ONE, 2020, 15, e0231667.	2.5	9
34	Anxiety and depressive symptoms are associated with poor sleep health during a period of COVID-19-induced nationwide lockdown: a cross-sectional analysis of adults in Jordan. BMJ Open, 2020, 10, e041995.	1.9	41
35	Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus–infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. Clinical Infectious Diseases, 2019, 68, 650-657.	5.8	21
36	Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Journal of Infectious Diseases, 2019, 220, 1629-1634.	4.0	8

#	Article	IF	Citations
37	Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study. EClinicalMedicine, 2019, 13, 91-100.	7.1	15
38	The HIV response and global health. Lancet, The, 2019, 393, 1696.	13.7	1
39	Host country responses to non-communicable diseases amongst Syrian refugees: a review. Conflict and Health, 2019, 13, 8.	2.7	59
40	Optimizing HIV prevention and treatment outcomes for persons with substance use in Central Asia. Current Opinion in HIV and AIDS, 2019, 14, 374-380.	3.8	11
41	Gender differences in the use of cardiovascular interventions in <scp>HIV</scp> â€positive persons; the D:A:D Study. Journal of the International AIDS Society, 2018, 21, e25083.	3.0	10
42	Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study. Lancet HIV,the, 2018, 5, e291-e300.	4.7	155
43	A timeâ€motion study of cardiovascular disease risk factor screening integrated into ⟨scp⟩HIV⟨/scp⟩ clinic visits in Swaziland. Journal of the International AIDS Society, 2018, 21, e25099.	3.0	9
44	Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions. Lancet, The, 2018, 391, 1939-1952.	13.7	143
45	A pragmatic approach to monitor and evaluate implementation and impact of differentiated <scp>ART</scp> delivery for global and national stakeholders. Journal of the International AIDS Society, 2018, 21, e25080.	3.0	15
46	Addressing chronic diseases in protracted emergencies: Lessons from HIV for a new health imperative. Global Public Health, 2018, 13, 227-233.	2.0	22
47	Abacavir use and risk of recurrent myocardial infarction. Aids, 2018, 32, 79-88.	2.2	15
48	Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in NewAYork city. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 9-17.	1.2	76
49	Building on the HIV platform. Aids, 2018, 32, S1-S3.	2.2	34
50	Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa. Aids, 2018, 32, S107-S113.	2.2	37
51	Integrating cardiovascular disease risk factor screening into HIV services in Swaziland. Aids, 2018, 32, S43-S46.	2.2	18
52	Persons living with <scp>HIV</scp> with advanced <scp>HIV</scp> disease: need for novel care models. Journal of the International AIDS Society, 2018, 21, e25210.	3.0	11
53	Cost-effectiveness of a combination strategy to enhance the HIV care continuum in Swaziland: Link4Health. PLoS ONE, 2018, 13, e0204245.	2.5	6
54	Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D:A:D Cohort Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 579-588.	2.1	38

#	Article	IF	CITATIONS
55	HIV Population Surveys â€" Bringing Precision to the Global Response. New England Journal of Medicine, 2018, 378, 1859-1861.	27.0	64
56	It's all in the timing: Acceptability of a financial incentive intervention for linkage to HIV care in the HPTN 065 (TLC-Plus) study. PLoS ONE, 2018, 13, e0191638.	2.5	7
57	Getting the balance right: Scaling-up treatment and prevention. Global Public Health, 2017, 12, 483-497.	2.0	4
58	Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet HIV,the, 2017, 4, e83-e92.	4.7	78
59	Willingness to use short-term oral pre-exposure prophylaxis (PrEP) by migrant miners and female partners of migrant miners in Mozambique. Culture, Health and Sexuality, 2017, 19, 1389-1403.	1.8	13
60	Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients. JAMA Internal Medicine, 2017, 177, 1083.	5.1	105
61	Design of the HPTN 065 (TLC-Plus) study: A study to evaluate the feasibility of an enhanced test, link-to-care, plus treat approach for HIV prevention in the United States. Clinical Trials, 2017, 14, 322-332.	1.6	31
62	Uptake of needle and syringe program services in the Kyrgyz Republic: Key barriers and facilitators. Drug and Alcohol Dependence, 2017, 179, 180-186.	3.2	16
63	Factors Associated with Use of Short-Term Pre-Exposure Prophylaxis for HIV Among Female Partners of Migrant Miners in Mozambique. AIDS Patient Care and STDs, 2017, 31, 528-534.	2.5	4
64	Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention. Journal of the International Association of Providers of AIDS Care, 2017, 16, 81-90.	1.5	5
65	"Testing, Testing― Multiple HIV-Positive Tests among Patients Initiating Antiretroviral Therapy in Ethiopia. Journal of the International Association of Providers of AIDS Care, 2017, 16, 546-554.	1.5	14
66	Selecting a viral load threshold for routine monitoring in resourceâ€limited settings: optimizing individual health and population impact. Journal of the International AIDS Society, 2017, 20, e25007.	3.0	31
67	Understanding low sensitivity of communityâ€based HIV rapid testing: experiences from the HPTN 071 (PopART) trial in Zambia and South Africa. Journal of the International AIDS Society, 2017, 20, 21780.	3.0	23
68	Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy. PLoS Medicine, 2017, 14, e1002278.	8.4	14
69	Effectiveness of a combination strategy for linkage and retention in adult HIV care in Swaziland: The Link4Health cluster randomized trial. PLoS Medicine, 2017, 14, e1002420.	8.4	59
70	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	8.4	17
71	The PREVENT study to evaluate the effectiveness and acceptability of a community-based intervention to prevent childhood tuberculosis in Lesotho: study protocol for a cluster randomized controlled trial. Trials, 2017, 18, 552.	1.6	7
72	Advanced Human Immunodeficiency Virus Disease at Diagnosis in Mozambique and Swaziland. Open Forum Infectious Diseases, 2017, 4, ofx156.	0.9	10

#	Article	IF	Citations
73	A Randomized-Controlled Trial of Computer-based Prevention Counseling for HIV-Positive Persons (HPTN 065). Journal of AIDS & Clinical Research, 2017, 08, .	0.5	9
74	A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. PLoS Medicine, 2017, 14, e1002292.	8.4	95
75	Pregnant and breastfeeding women: A priority population for HIV viral load monitoring. PLoS Medicine, 2017, 14, e1002375.	8.4	44
76	Reaching global HIV/AIDS goals: What got us here, won't get us there. PLoS Medicine, 2017, 14, e1002421.	8.4	35
77	How Can the Health System Retain Women in HIV Treatment for a Lifetime? A Discrete Choice Experiment in Ethiopia and Mozambique. PLoS ONE, 2016, 11, e0160764.	2.5	36
78	Factors associated with initiation of antiretroviral therapy in the advanced stages of HIV infection in six Ethiopian HIV clinics, 2012 to 2013. Journal of the International AIDS Society, 2016, 19, 20637.	3.0	48
79	Transitioning to Country Ownership of HIV Programs in Rwanda. PLoS Medicine, 2016, 13, e1002075.	8.4	12
80	China's health assistance to Africa: opportunism or altruism?. Globalization and Health, 2016, 12, 83.	4.9	27
81	Population health and individualized care in the global AIDS response. Aids, 2016, 30, 2145-2148.	2.2	27
82	Gender Differences and Psychosocial Factors Associated with Quality of Life Among ART Initiators in Oromia, Ethiopia. AIDS and Behavior, 2016, 20, 1682-1691.	2.7	14
83	Early initiation of antiretroviral therapy: debate over? – Authors' reply. Lancet Infectious Diseases, The, 2016, 16, 769-770.	9.1	0
84	Costs of Expanded Rapid HIV Testing in Four Emergency Departments. Public Health Reports, 2016, 131, 71-81.	2.5	19
85	Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine, 2016, 14, 61.	5 . 5	100
86	From START to finish: implications of the START study. Lancet Infectious Diseases, The, 2016, 16, 13-14.	9.1	10
87	Identifying Perceived Barriers along the HIV Care Continuum. Journal of the International Association of Providers of AIDS Care, 2016, 15, 291-300.	1.5	24
88	HIV Care and Treatment Beliefs among Patients Initiating Antiretroviral Treatment (ART) in Oromia, Ethiopia. AIDS and Behavior, 2016, 20, 998-1008.	2.7	12
89	Can the Success of HIV Scale-Up Advance the Global Chronic NCD Agenda?. Global Heart, 2016, 11, 403.	2.3	22
90	Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, e44-e51.	2.1	38

#	Article	IF	CITATIONS
91	The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial. Implementation Science, 2015, 10, 101.	6.9	19
92	Association Between HIV Programs and Quality of Maternal Health Inputs and Processes in Kenya. American Journal of Public Health, 2015, 105, S207-S210.	2.7	11
93	Missed Opportunities to Address Cardiovascular Disease Risk Factors amongst Adults Attending an Urban HIV Clinic in South Africa. PLoS ONE, 2015, 10, e0140298.	2.5	23
94	Putting quality at the heart of HIV programs. Aids, 2015, 29, S119-S120.	2.2	3
95	Ebola: the real lessons from HIV scale-up. Lancet Infectious Diseases, The, 2015, 15, 506.	9.1	2
96	HIV Treatment-As-Prevention Research: Taking the Right Road at the Crossroads. PLoS Medicine, 2015, 12, e1001800.	8.4	7
97	Innovation to confront Ebola in Sierra Leone: the community-care-centre model. The Lancet Global Health, 2015, 3, e361-e362.	6.3	9
98	Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. Journal of the International AIDS Society, 2014, 17, 19512.	3.0	29
99	Characteristics and Outcomes among Older HIV-Positive Adults Enrolled in HIV Programs in Four Sub-Saharan African Countries. PLoS ONE, 2014, 9, e103864.	2.5	40
100	Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study. Journal of the International AIDS Society, 2014, 17, 19516.	3.0	17
101	End of AIDS—Hype versus hope. Science, 2014, 345, 166-166.	12.6	9
102	Letting HIV Transform Academia â€" Embracing Implementation Science. New England Journal of Medicine, 2014, 370, 1679-1681.	27.0	24
103	HIV, Tuberculosis, and Noncommunicable Diseases. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S87-S95.	2.1	63
104	Family Matters. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, S243-S249.	2.1	15
105	Geographic Utilization of Gift Cards Used for Financial Incentives to Encourage Viral Suppression: Findings from HPTN 065. AIDS Research and Human Retroviruses, 2014, 30, A287-A287.	1.1	1
106	The Impact of Implementing a Financial Incentive Program for Viral Suppression on the Clinic Environment: A Qualitative Substudy of HPTN 065. AIDS Research and Human Retroviruses, 2014, 30, A104-A105.	1.1	1
107	A Paradigm Shift: Focus on the HIV Prevention Continuum. Clinical Infectious Diseases, 2014, 59, S12-S15.	5.8	80
108	Understanding of Viral Load among Participants Receiving Financial Incentives for ART Adherence: Findings from a Qualitative Substudy of HPTN 065. AIDS Research and Human Retroviruses, 2014, 30, A105-A105.	1.1	0

#	Article	IF	Citations
109	Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet, The, 2014, 384, 241-248.	13.7	767
110	Antiretroviral Therapy for Prevention Is a Combination Strategy. Current HIV/AIDS Reports, 2013, 10, 152-158.	3.1	32
111	When to Start ART in Africa. New England Journal of Medicine, 2013, 368, 2238-2238.	27.0	1
112	Clinical trials provide <i>the</i> evidence critical for patient empowerment. Journal of the International AIDS Society, 2013, 16, 18811.	3.0	0
113	The Problem of Late ART Initiation in Sub-Saharan Africa: A Transient Aspect of Scale-up or a Long-term Phenomenon?. Journal of Health Care for the Poor and Underserved, 2013, 24, 359-383.	0.8	91
114	Consumption Rate of a Wholeâ€Food Macronutient Supplement for Adults Initiating Antiretroviral Therapy in Kenya. FASEB Journal, 2013, 27, 619.7.	0.5	0
115	PEPFAR Programs Linked To More Deliveries In Health Facilities By African Women Who Are Not Infected with HIV. Health Affairs, 2012, 31, 1478-1488.	5.2	27
116	The HIV care continuum. Aids, 2012, 26, 1735-1738.	2.2	101
117	Scale-up of HIV Treatment Through PEPFAR. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, S96-S104.	2.1	92
118	A Chronicle of Hope and Promise. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, S49-S50.	2.1	0
119	Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the United States. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, e65-e69.	2.1	21
120	Game Changers: Why Did the Scale-Up of HIV Treatment Work Despite Weak Health Systems?. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S61-S63.	2.1	40
121	Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. Aids, 2011, 25, 2295-2299.	2.2	35
122	No Need for Apologies. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S68-S71.	2.1	0
123	Bridging the Divide. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, S59-S60.	2.1	4
124	Maternal and Infant Outcomes With Concurrent Treatment of Tuberculosis and HIV Infection in Pregnant Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e63-e66.	2.1	5
125	Integration of Antiretroviral Therapy with Tuberculosis Treatment. New England Journal of Medicine, 2011, 365, 1492-1501.	27.0	451
126	Why reinvent the wheel? Leveraging the lessons of HIV scale-up to confront non-communicable diseases. Global Public Health, 2011, 6, 247-256.	2.0	155

#	Article	IF	Citations
127	CD4+ Cell Count Testing More Effective Than HIV Disease Clinical Staging in Identifying Pregnant and Postpartum Women Eligible for Antiretroviral Therapy in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 404-410.	2.1	43
128	Initiation of antiretroviral therapy among pregnant women in resource-limited countries: CD4+ cell count response and program retention. Aids, 2010, 24, 515-524.	2.2	27
129	The HIV Epidemic in the United States: A Time for Action. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S63.	2.1	5
130	Antiretroviral Therapy: A Promising HIV Prevention Strategy?. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, S116-S121.	2.1	23
131	Keeping health facilities safe: one way of strengthening the interaction between disease-specific programmes and health systems. Tropical Medicine and International Health, 2010, 15, 1407-1412.	2.3	36
132	Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 491-501.	2.8	309
133	Impact of Antiretroviral Therapy on Incidence of Pregnancy among HIV-Infected Women in Sub-Saharan Africa: A Cohort Study. PLoS Medicine, 2010, 7, e1000229.	8.4	177
134	Addressing Research Priorities for Prevention of HIV Infection in the United States. Clinical Infectious Diseases, 2010, 50, S149-S155.	5.8	40
135	AIDS in America — Forgotten but Not Gone. New England Journal of Medicine, 2010, 362, 967-970.	27.0	140
136	The Impact of HIV Scale-Up on Health Systems: A Priority Research Agenda. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, S6-S11.	2.1	43
137	Health Systems Exist for Real People. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, S1-S2.	2.1	10
138	Lessons From Harlem: Relevance to a Global Epidemic. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, S24-S26.	2.1	3
139	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, The, 2008, 371, 1417-1426.	13.7	809
140	The President's Emergency Plan for AIDS Relief â€" Is the Emergency Over?. New England Journal of Medicine, 2008, 359, 553-555.	27.0	38
141	HIV-Associated Tuberculosis: Diagnostic and Treatment Challenges. Seminars in Respiratory and Critical Care Medicine, 2008, 29, 525-531.	2.1	58
142	Scale-up of HIV care and treatment: can it transform healthcare services in resource-limited settings?. Aids, 2007, 21, S65-S70.	2.2	62
143	Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. New England Journal of Medicine, 2007, 356, 1723-1735.	27.0	1,393
144	Antiretroviral Treatment and Prevention of Peripartum and Postnatal HIV Transmission in West Africa: Evaluation of a Two-Tiered Approach. PLoS Medicine, 2007, 4, e257.	8.4	118

#	Article	IF	CITATIONS
145	Prevention of mother-to-child transmission services as a gateway to family-based human immunodeficiency virus care and treatment in resource-limited settings: rationale and international experiences. American Journal of Obstetrics and Gynecology, 2007, 197, S101-S106.	1.3	63
146	Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. Aids, 2006, 20, 1109-1116.	2.2	69
147	Reproductive decisions in HIV-infected individuals. Lancet, The, 2005, 366, 698-700.	13.7	31
148	Focus on Women: Linking HIV Care and Treatment with Reproductive Health Services in the MTCT-Plus Initiative. Reproductive Health Matters, 2005, 13, 136-146.	1.2	66
149	Predictors of Hypertension and Changes of Blood Pressure in HIV-Infected Patients. Antiviral Therapy, 2005, 10, 811-823.	1.0	103
150	Expanding access to antiretroviral therapy through the public sectorthe challenge of retaining patients in long-term primary care. South African Medical Journal, 2004, 94, 273-4.	0.6	13
151	A Review of Efficacy Studies of 6-Month Short-Course Therapy for Tuberculosis among Patients Infected with Human Immunodeficiency Virus: Differences in Study Outcomes. Clinical Infectious Diseases, 2001, 32, 623-632.	5.8	83
152	Discontinuation of Prophylaxis against Mycobacterium avium Complex Disease in HIV-Infected Patients Who Have a Response to Antiretroviral Therapy. New England Journal of Medicine, 2000, 342, 1085-1092.	27.0	146
153	Safer sex strategies for women: The hierarchical model in methadone treatment clinics. Journal of Urban Health, 1999, 76, 62-72.	3.6	17
154	Oral candidiasis in HIV infection: predictive value and comparison of findings in injecting drug users and homosexual men. Journal of Oral Pathology and Medicine, 1997, 26, 237-243.	2.7	31
155	Difference in clinical implications of CD4 counts among HIV-infected homosexual men and injection drug using men and women. Statistics in Medicine, 1995, 14, 1889-1900.	1.6	2
156	The Effect of Methadone on Immunological Parameters among HIV-Positive and HIV-Negative Drug Users. American Journal of Drug and Alcohol Abuse, 1994, 20, 317-329.	2.1	19